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Abstract
Background: Increased fasting plasma glucose (FPG), which includes impaired fasting glucose (IFG), impaired
glucose tolerance (IGT), and diabetes, is a risk factor for arterial stiffness. While IFG is widely accepted as a
cardiovascular risk factor, recent studies have argued that subjects with high-normal glucose level were
characterized by a high incidence of cardiovascular disease. The purpose of this study is to investigate the
relationship between FPG and arterial stiffness in non-diabetic healthy subjects.
Methods: We recruited 697 subjects who visited the health promotion center of a university hospital from May
2007 to August 2008. Age, sex, body mass index (BMI), resting heart rate, smoking habits, alcohol intake, exercise,
blood pressure, medical history, FPG, lipid profile, high sensitivity C-reactive protein (hs-CRP), and Brachial-ankle
pulse wave velocity (ba-PWV) were measured. We performed correlation and multiple linear regression analyses to
divide the research subjects into quartiles: Q1(n = 172), 65 mg/dL ≤FPG < 84 mg/dL; Q2(n = 188), 84 mg/dL ≤FPG
< 91 mg/dl; Q3(n = 199), 91 mg/dL ≤FPG < 100 mg/dL; Q4(n = 138), 100 mg/dL ≤FPG < 126 mg/dL.
Results: FPG has an independent, positive association with ba-PWV in non-diabetic subjects after correcting for
confounding variables, including age, sex, BMI, blood pressure, resting heart rate, hs-CRP, lipid profile, and
behavioral habits. The mean ba-PWV of the high-normal glucose group (Q3, 1384 cm/s) was higher than that of
the low-normal glucose group (1303 ± 196 cm/s vs.1328 ± 167 cm/s, P < 0.05). The mean ba-PWV value in the IFG
group (1469 ± 220 cm/s) was higher than that in the normoglycemic group (P < 0.05, respectively).
Conclusions: An increase in FPG, even within the normal range, was associated with aggravated arterial stiffness.
Further research is needed to determine the glycemic target value for the prevention of arterial stiffness in clinical
and public health settings.
Background
Increased fasting plasma glucose (FPG), which includes
impaired fasting glucose (IFG), impaired glucose toler-
ance (IGT), and diabetes, is a risk factor for arterial stiff-
ness and cardiovascular disease [1-4]. Because there is
no threshold glucose level to indicate the development
of vascular disease, determining the appropriate target
FPG level for the prevention of cardiovascular risk is a
topic of active research [5-7]. While IFG is widely
accepted as a cardiovascular risk factor, recent studies
have demonstrated that subjects with high-normal
glucose level are characterized by a high incidence of
cardiovascular disease [8-10]. This finding indicates that,
even in the normal range, increased FPG can be asso-
ciated with aggravation of arterial stiffness, which is
considered an early marker of atherosclerosis.
Arterial stiffness can be easily and noninvasively
assessed by measuring the pulse wave velocity (PWV)
[11,12]. Brachial-ankle PWV (ba-PWV) is a suitable
measure for screening for vascular dysfunction and the
development of atherosclerosis in a preventive setting
[13,14]. We assessed whether the FPG level is associated
with arterial stiffness by measuring ba-PWV in non-
diabetic healthy subjects with no history of cardiovascular
disease, hypertension, or dyslipidemia.
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Study Population
We recruited 856 non-diabetic subjects who visited the
health promotion center of a university hospital from
May 2007 to August 2008. We excluded 152 subjects
with history of anti-diabetes medication; anti-hypertensive
medication; lipid-lowering medication; stroke; or cardio-
vascular disease, such as coronary heart disease, peripheral
arterial disease, arrhythmia, congestive heart failure, or
valvular heart disease. We also excluded six subjects who
had extremely low FPG levels (50-65 mg/dL) and one sub-
ject who had a low ankle-brachial index (ABI) (<0.9),
which suggested the subject might have had peripheral
arterial occlusive disease. After the exclusions, 697 subjects
were included in this study. The institutional review board
of Gangnam Severance Hospital, Yonsei University
College of Medicine approved this study, and informed
consent was obtained from each participant.
The study sample was divided into four groups accord-
ing to FPG level. Using the diagnostic criteria of the
American Diabetes Association [15], after grouping the
IFG subjects (Q4, 100 mg/dL ≤FPG<126 mg/dL), FPG
levels were categorized into quartiles: Q1(n = 172),
65 mg/dL ≤FPG<84 mg/dL; Q2(n = 188), 84 mg/dL
≤FPG<91 mg/dl; and Q3(n = 199), 91 mg/dL ≤FPG<
100 mg/dL, Q4(n = 138):100 mg/dL ≤FPG<126 mg/dL.
Blood pressure and resting heart rate were measured after
resting for more than five minutes. Anthropometric mea-
surements were used to calculate the body mass index
(BMI). To reduce inter-observer variation in measure-
ments, one researcher measured all anthropometric para-
meters throughout the study. A questionnaire was used to
obtain information about participant medical history and
lifestyle, such as exercise, smoking habits, and alcohol
ingestion. Subjects were instructed to refrain from alcohol
on the day before testing and from smoking, coffee, tea,
and pain medication on the day of measurement.
After an overnight fast, serum glucose, total choles-
terol and high density lipoprotein (HDL)-cholesterol
levels were measured via enzymatic procedures using an
autoanalyser (Bayer, Terrytown, NY, USA). Non-high
density lipoprotein (HDL) cholesterol was calculated by
subtracting HDL-cholesterol from total cholesterol.
Non-HDL cholesterol includes all known potential
atherogenic lipid particles. All variables were adjusted
according to non-HDL cholesterol because it is a useful
predictor of risk for cardiovascular disease [16,17].
High-sensitivity C-reactive protein (hs-CRP) was mea-
sured using a latex-enhanced immunoturbidimetric
assay in an ADVIA 1650 Chemistry System (Bayer).
PWV Measurement
The ba-PWV was measured using a volume plethysmo-
graphic instrument (PWV/ABI, Colin Co, Komaki, Japan).
This device records a phonocardiogram, electrocardio-
gram, volume pulse form, and arterial blood pressure at
the left and the right brachial arteries and ankles. The
ba-PWV was calculated using time-phase analysis between
the right brachial artery pressure and the volume wave-
f o r m sa tb o t ha n k l e s .T h ed i s t a n c eb e t w e e nt h er i g h t
brachium and the ankle was estimated based on the
subject’s height. We used the mean ba-PWV in analyses
because the right and the left ba-PWV are significantly
correlated [18]. Both ba-PWV values were measured after
allowing the patient to rest in the supine position for at
least five minutes in an air-conditioned room (24 to 26°C).
The validity, reliability, and reproducibility of this instru-
ment were assessed in a previous study [19].
Statistical Analysis
SAS 9·1 was used for statistical analyses (SAS Institute,
Cary, NC, USA). Mean values of the clinical characteris-
tics were compared among the four subject groups
using one-way analysis for continuous variables and the
Chi-squared test for categorical variables. Because of the
skewed distribution of hs-CRP, this parameter was loga-
rithmically transform; however, untransformed raw data
are presented for the mean ± standard deviation (SD) in
tables. Pearson’s correlation coefficients were calculated
to evaluate the relationships between ba-PWV and clini-
cal variables. After adjusting for age, sex, blood pressure
(systolic/diastolic), body mass index, resting heart rate,
hs-CRP, HDL-cholesterol, non-HDL cholesterol, exer-
cise, smoking, and alcohol ingestion, a multiple linear
regression analysis was performed to identify any inde-
pendent associations between ba-PWV and FPG level.
The mean ba-PWV of the quartile was analyzed using
an ANCOVA test considering confounding factors.
P values less than 0.05 were considered statistically
significant.
Results
T h ec h a r a c t e r i s t i c so ft h e6 97 subjects enrolled in this
study are shown in Table 1 .T h es u b j e c t sw e r ea d u l t s
between 20 and 79 years of age, with a mean age of 52.3 ±
9.1 years. The mean glucose levels were as follows: Q1
(77.8 ± 4.2 mg/dl), Q2 (87.2 ± 2.0 mg/dl), Q3 (94.7 ±
2.5 mg/dl), and Q4 (107.0 ± 6.2 mg/dl). In addition, BMI,
systolic blood pressure, diastolic blood pressure, hs-CRP,
resting heart rate, non-HDL cholesterol, male: female
ratio, and alcohol ingestion were also different between
the four groups (P<0.01 vs. P<0.05, respectively).
In age-adjusted Pearson’s correlations, ba-PWV level
was positively correlated with FPG level, systolic blood
pressure, diastolic blood pressure, BMI, resting heart
rate, hs-CRP, and non-HDL cholesterol, and ba-PWV
level was negatively correlated with HDL-cholesterol, as
shown in Table 2. Smoking habits, alcohol ingestion,
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mean PWV increased according to FPG quartile, as
shown in Table 1 .T h em e a nb a - P W Vv a l u eo ft h e
high-normal glucose group (Q3) was higher than those
of the low-normal glucose groups (Q1, Q2). Even after
adjusting the parameters, the mean ba-PWV in Q3 was
higher than that of the low-normal glucose group (Q1).
The mean ba-PWV value in the IFG group (Q4) (1438
cm/s) was higher than those of the normal glucose
groups (P < 0.05; Figure 1) after adjustments for age,
sex, body mass index, systolic blood pressure, diastolic
blood pressure, resting heart rate, HDL-cholesterol,
non-HDL cholesterol, and hs-CRP (logarithmically
transformed).
Through multiple linear regression analysis, ba-PWV
was found to be independently and positively associated
with FPG, as shown in Table 3. Ba-PWV was indepen-
dently and negatively associated with BMI but was not
associated with diastolic blood pressure, male: female
ratio, HDL-cholesterol, or non-HDL cholesterol.
Table 1 Clinical and metabolic characteristics of study participants according to fasting plasma glucose quartile (n = 697)
FPG Q1 Q2 Q3 Q4 P value
(n = 172) (n = 188) (n = 199) (n = 138)
Mean FPG 77.8 ± 4.2 87.2 ± 2.0 94.7 ± 2.6 107.0 ± 6.2 <0.01
Age (y) 48.9 ± 9.0 50.6 ± 9.1 54.0 ± 8.8 54.2 ± 8.2 <0.01
Men (%) 53.1 60.9 69.1 60.8 <0.01
BMI
1 (kg/m
2) 22.7 ± 2.8 23.2 ± 3.1 23.8 ± 2.7 24.7 ± 2.7 <0.01
SBP
2 (mmHg) 117 ± 15 118 ± 14 124 ± 15 127 ± 17 <0.01
DBP
3 (mmHg) 73 ± 9 75 ± 9 78 ± 9 80 ± 10 <0.01
Resting heart rate (beats/min) 72 ± 11 73 ± 11 74 ± 11 75 ± 13 <0.05
hs-CRP
4 (mg/dL) 0.91 ± 0.87 0.97 ± 1.03 1.07 ± 0.99 1.24 ± 0.98 <0.01
HDL-cholesterol (mg/dL) 54.7 ± 13.3 53.0 ± 12.9 51.0 ± 11.9 49.9 ± 11.6 <0.01
Non-HDL cholesterol (mg/dL) 134.1 ± 34.6 136.7 ± 31.9 144.5 ± 33.0 150.5 ± 38.0 <0.01
Ba-PWV(cm/s) 1303 ± 196 1328 ± 167 1384 ± 216 1469 ± 220 <0.01
Smoker
5 (%) 27.9 20.1 23.1 26.1 NS
8
Alcohol
6 (%) 58.1 56.5 62.1 74.0 <0.01
Exercise
7 (%) 76.2 71.1 80.0 75.0 NS
8
Data are shown as the mean ± standard deviation and percentage (%).
P values were calculated using the ANOVA and X
2-tests.
1body mass index;
2systolic blood pressure;
3diastolic blood pressure;
4high sensitivity C-reactive protein;
5 current smokers;
6alcohol ingestion≥1 time a week;
7regular exercise ≥4 hours a week;
8Not significant.
Table 2 Age-adjusted correlations between brachial-ankle
pulse wave velocity and various parameters (n = 697)
Pulse Wave Velocity
Rp -value
FPG
1 (mg/dL) 0.278 <0.01
BMI
2 (kg/m
2) 0.089 <0.05
SBP
3 (mmHg) 0.502 <0.01
DBP
4 (mmHg) 0.472 <0.01
RHR
5(beats/min) 0.169 <0.01
hs-CRP
6(mg/dL) 0.167 <0.01
HDL-cholesterol (mg/dL) -0.146 <0.01
Non-HDL cholesterol (mg/dL) 0.111 <0.01
Current smoking 0.005 NS
7
Alcohol ingestion -0.005 NS
7
Exercise 0.015 NS
7
Coefficients (r) and p-values are calculated using the age-adjusted Pearson’s
correlation model.
1fasting plasma glucose;
2body mass index;
3systolic blood pressure;
4diastolic
blood pressure;
5resting heart rate;
6 high sensitivity C-reactive protein,
logarithmically transformed values;
7NS, not significant.
Figure 1 Mean values of brachial-ankle pulse wave velocity
according to fasting plasma glucose quartile in non-diabetic
healthy subjects.* P<0.05 vs. Q1 and Q2, § P<0.05 vs. Q1, Q2, and
Q3, ¶ P<0.05 vs. Q1 Model 1; adjusted for age, sex. Model 2;
adjusted for age, sex, systolic blood pressure, diastolic blood
pressure, BMI, resting heart rate, Hs-CRP, HDL-cholesterol, and non
HDL-cholesterol.
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In this study, FPG was positively and independently
associated with the ba-PWV in non-diabetic healthy
adults after correcting for confounding variables. In a
recent study, resting heart rate, as an indicator of vascu-
lar autonomic balance, was associated with ba-PWV
[20]. Therefore, we included resting heart rate as a con-
founding factor in our analyses. We also found that rest-
ing heart rate was associated with the ba-PWV in non-
diabetic healthy adults, and FPG was independently
associated with ba-PWV after adjusting for resting heart
rate and other confounding factors. In a previous study,
the ba-PWV level increased from normoglycemic to dia-
betic subjects. Ohnish et al. observed a higher ba-PWV
in the IFG than in the normal glucose group, but the
authors did not adjust for important confounding fac-
tors, such as age, blood pressure, or BMI [13]. Lin Xu et
al. showed that, when HbA1c was increased, the ba-
PWV of normoglycemic subjects, who were grouped
according to hemoglobin A1c (HbA1c), increased. How-
ever, the authors mentioned that normoglycemic sub-
jects grouped according to FPG did not show the same
correlation [21]. Lukich et al. found that 284 Caucasian
subjects had a positive correlation among FPG, HbA1c,
and central artery PWV, and that increased arterial stiff-
ness started at the IFG level according to comparisons
of normal glucose, IFG, and diabetes [1].
Based on the difference between the mean ba-PWV
values in our study, arterial stiffness may already be
occurring in subjects with FPG levels within the normal
range [22]. This is the first study to show that patients
with high-normal FPG have increased arterial stiffness
as measured by ba-PWV. There are some studies that
have shown that high normoglycemic status is a risk
factor of cardiovascular disease. Twenty-two years of fol-
low-up demonstrated that non-diabetic men with FPG
level > 85 mg/dl had a 1.4-fold higher risk of cardiovas-
cular death than did men with lower FPG [23]. In a pre-
vious case-controlled study, after excluding patients with
diabetes, patients with impaired glucose tolerance and
impaired fasting glucose (FPG > 5.2 mmol/l) were found
to be 2.7 times (95% CI 1.5- 4.8) more likely to experi-
ence myocardial infarction [24]. Our results support the
hypothesis that high-normal FPG level is associated with
target organ damage and vascular dysfunction and
extended the current knowledge by demonstrating a lin-
ear, independent relationship between FPG and arterial
stiffness in non-diabetic healthy adults.
We excluded six subjects with extremely low FPG
level (50-65 mg/dL), even though they had no hypogly-
cemic symptoms, in order to overcome interpretive diffi-
culty during statistical analysis. These subjects had
higher ba-PWV values compared to those of subjects
with FPG level between 65-84 mg/dL. We believe that
very low FPG does not protect against arterial stiffness,
and the relationship between FPG and ba-PWV is a J-
shaped curve over the entire range of glucose levels. We
suggest that a threshold should be established to avoid
arterial stiffness in patients with glucose levels that are
within the normal range.
There are some limitations to the generalizability of
o u rr e s u l t s .F i r s t ,a st h i ss t u d yw a sc r o s s - s e c t i o n a la n d
was carried out in only one location, it was not possible
to establish the exact pathophysiology linking fasting
plasma glucose and ba-PWV because we did not con-
sider the characteristics of diverse local environments.
S e c o n d ,u pt of i v ep e r c e n to fs u b j e c t sw i t hI F Gw i l l
appear to have diabetes according to 2-hour glucose tol-
erance testing [25,26]. True-DM and IFG groups were
not demarcated in the glucose tolerance test, implying
that some people in the IFG group may actually have
had DM. Finally, we could not explain the influence of
insulin, and further study is needed to adjust for insulin
resistance [27,28].
Although this study has some limitations, it is the first
attempt to compare arterial stiffness between high-normal
FPG (91-100 mg/dL) and low-normal FPG (65-84 mg/dL)
subjects as measured by ba-PWV for the purpose of early
detection and prevention of arterial stiffness.
Conclusions
We demonstrated that FPG level, even within the nor-
mal range, is associated with aggravation of arterial stiff-
ness in non-diabetic healthy subjects. Further research is
needed to determine the optimal glycemic target value
for the prevention of arterial stiffness in clinical and
public health settings.
Table 3 Multiple linear regression analyses conducted to
assess independent relationships between pulse wave
velocity and clinical variables
Variable Pulse Wave Velocity
Regression coefficient (95% CI) P value
FPG 1.40(0.26,2.55) <0.01
Age 9.60(8.30,10.91) <0.01
Sex -21.61(-47.97,4.75) NS
BMI -12.34(-17.12,-7.56) <0.01
SBP 5.24(3.54,6.96) <0.01
DBP 1.29(-1.56,4.13) NS
RHR 1.66(0.59,2.72) <0.01
hs-CRP 15.42(2.01,28.83) <0.05
HDL-cholesterol -0.58(-1.59,0.43) NS
Non-HDL cholesterol 0.23(-0.12,0.57) NS
R
2= 0.48, adjusted R
2= 0.47
P < 0.001
FPG, fasting plasma glucose; SBP, systolic blood pressure; DBP, diastolic blood
pressure; Sex: male, 1: female, 2; BMI, body mass index; hs-CRP, high-sensitivity
C-reactive protein; NS, not significant.
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